Janux Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
JANX$12.76-27.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Collaboration revenue | $8,083 | $8,612 |
| Operating expenses: | ||
| Research and development | 54,922 | 53,441 |
| General and administrative | 26,140 | 22,262 |
| Total operating expenses | 81,062 | 75,703 |
| Loss from operations | (72,979) | (67,091) |
| Other income: | ||
| Interest income | 14,686 | 4,032 |
| Total other income | 14,686 | 4,032 |
| Net loss | $(58,293) | $(63,059) |
| Other comprehensive gain (loss): | ||
| Unrealized gain (loss) on available-for-sale securities, net | 2,200 | (1,265) |
| Comprehensive loss | $(56,093) | $(64,324) |
| Net loss per common share, basic and diluted | $(1.32) | $(1.52) |
| Weighted-average shares of common stock outstanding, basic and diluted | 44,016,283 | 41,469,631 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.